DelveInsight’s Nontuberculous Mycobacteria Infection Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Nontuberculous Mycobacteria Infection in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Nontuberculous Mycobacteria Infection (NTM) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2017-2030
The DelveInsight Nontuberculous Mycobacteria Infection (NTM) market report gives the thorough understanding of the Nontuberculous Mycobacteria Infection (NTM) by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US, EU5 and Japan.
Nontuberculous Mycobacterial (NTM) Infections Disease Understanding and Treatment Algorithm
Nontuberculous Mycobacteria Infection (NTM) is caused by nontuberculous mycobacteria which are ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy personnel and those with compromised immune systems.
The report covers the details of conventional and current medical therapies available in the NTM market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.
Nontuberculous Mycobacterial (NTM) Infections Epidemiology
The Nontuberculous Mycobacteria Infection epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool, treatable patient pool and the prevalence based on various parameters such as species type and severity in the US, EU5 and Japan.
Key Findings
According to DelveInsight, the prevalent population of NTM in 7MM is expected to increase at a CAGR of 0.6% for the study period i.e. 2017–2030.
United States has the highest number of prevalent cases of NTM infections among all the 7MM countries.
According to a study by Wagner et al. (2014), the prevalence of PNTM in Europe ranged from 5.9 per 100,000 in Spain to 6.5 per 100,000 in the UK.
Country Wise- Nontuberculous Mycobacterial (NTM) Infections Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed prevalent cases, total treatable population, prevalence based on species, and prevalence based on severity) scenario of Nontuberculous Mycobacteria Infection in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.
Nontuberculous Mycobacterial (NTM) Infections Drug Chapters
This segment of the NTM Drug report encloses the detailed analysis of the emerging drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.
As majority of clinical manifestations of NTM infections are related to lung infection, the treatment regimen mainly includes the usage of antimycobacterial therapy. Thus, owing to the symptomatic treatment in target patient population, the current therapeutic revenue of NTM infections covered in the report solely focuses on the market revenue generated by antibiotics used for the management of NTM lung infection. These include oral, intravenous as well as inhaled antibiotics.
Marketed Drugs
Arikayce: Insmed
Arikayce (amikacin) is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of MAC lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of six consecutive months of a multidrug background regimen therapy.
Nontuberculous Mycobacterial (NTM) Infections Emerging Drugs
RHB-204: RedHill Biopharma
RHB-204 (Clarithromycin/rifabutin/clofazimine) is a proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties.
Nontuberculous Mycobacterial (NTM) Infections Market Outlook
The NTM market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers.
This segment gives a through detail of emerging therapies and other promising therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Nontuberculous Mycobacteria Infection in 7MM was found to be USD 1,815.1 Million in 2017.
Key Findings
This section includes a glimpse of the Nontuberculous Mycobacterial (NTM) Infections market in 7MM.
The United States Market Outlook
This section provides the total Nontuberculous Mycobacterial (NTM) Infections market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Nontuberculous Mycobacterial Infections market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Nontuberculous Mycobacterial (NTM) Infections market size and market size by therapies in Japan is also mentioned.
Nontuberculous Mycobacterial (NTM) Infections Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Nontuberculous Mycobacterial Infections market or expected to get launched in the market during the study period 2017-2030. The analysis covers Nontuberculous Mycobacterial (NTM) Infections market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of Nontuberculous Mycobacterial Infections market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Nontuberculous Mycobacterial (NTM) Infections Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Nontuberculous Mycobacterial (NTM) Infections key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Nontuberculous Mycobacterial (NTM) Infections emerging therapies.
Reimbursement Scenario in Nontuberculous Mycobacterial (NTM) Infections
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Nontuberculous Mycobacterial (NTM) Infections domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Nontuberculous Mycobacterial Infections market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Nontuberculous Mycobacterial (NTM) Infections Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
